Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli: A Prospective Controlled Evaluation

Neonatal Meningitis Cooperative Study Group

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

Original languageEnglish (US)
Pages (from-to)1427-1432
Number of pages6
JournalJAMA - Journal of the American Medical Association
Volume252
Issue number11
DOIs
StatePublished - Sep 21 1984

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli: A Prospective Controlled Evaluation'. Together they form a unique fingerprint.

Cite this